MPT Product Development Database

This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
Hormonal/Non-HormonalDelivery RouteDelivery MethodDevelopment Stage
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
Key Word Search   

31 product(s) found

BioRings TM IVR

MPT in Development

Active Ingredient:
  • Ascorbic Acid
  • Boc-Lysinated Betulonic Acid
  • Ferrous Gluconate
  • Polyamino-Polycarboxlic Acid
  • Tenofovir (TFV)
  • Hormonal/Non-Hormonal:
  • BioRings LLC
  • Funding:
  • Unspecified
  • Development Stage:
    Preclinical – Early (P1)
    Delivery Route & Method:
    Topical - Intravaginal Ring (IVR)
    Mechanism of Action:
    Nanoporous hydrophilic polymeric hydrogel and non-hormonal contraception.
    Product Indications:
  • HIV
  • Pregnancy
  • Description:
    Similar hydrophilic polymeric hydrogel contraceptive ring (OvaPrene) currently in phase 2 study. Betulonic acids are very early in preclinical anti-HIV development.
    Useful Links:

    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    © Copyright 2019, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, an organization dedicated to advancing the comprehensive sexual and reproductive health of women and girls worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.